

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/342965517>

Managing Central Venous Access during a Healthcare Crisis

Article in *Journal of Vascular Surgery* · July 2020

DOI: 10.1016/j.jvs.2020.06.112

CITATIONS

0

READS

47

97 authors, including:



Peter F Lawrence

University of California, Los Angeles

93 PUBLICATIONS 1,338 CITATIONS

SEE PROFILE



Robert Cuff

Spectrum Health

45 PUBLICATIONS 487 CITATIONS

SEE PROFILE



Sherene Shalhub

University of Washington Seattle

98 PUBLICATIONS 984 CITATIONS

SEE PROFILE



Christopher J Abularrage

Johns Hopkins Medicine

177 PUBLICATIONS 2,172 CITATIONS

SEE PROFILE

Some of the authors of this publication are also working on these related projects:



Simulation [View project](#)



Rectal Prolapse [View project](#)



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Journal Pre-proof



Managing Central Venous Access during a Healthcare Crisis

Tristen T. Chun, MD, MS, Dejah R. Judelson, MD, David Rigberg, MD, Peter F. Lawrence, MD, Robert Cuff, MD, Sherene Shalhub, MD, MPH, Max Wohlauer, MD, Christopher J. Abularrage, MD, Papapetrou Anastasios, MD, PhD, MSc, Shipra Arya, MD, SM, Bernadette Aulivola, MD, MS, Melissa Baldwin, MD, Donald Baril, MD, Carlos F. Bechara, MD, William E. Beckerman, MD, Christian-Alexander Behrendt, MD, Filippo Benedetto, MD, Lisa F. Bennett, MD, MS, Kristofer M. Charlton-Ouw, MD, Amit Chawla, MD, Matthew C. Chia, MD, Sungsin Cho, MD, PhD, Andrew M.T.L. Choong, MBBS, PhD, Elizabeth L. Chou, MD, Anastasiadou Christiana, MD, Raphael Coscas, MD, PhD, Giovanni De Caridi, MD, PhD, Sharif Ellozy, MD, Yana Etkin, MD, Peter Faries, MD, Adrian T. Fung, MD, Andrew Gonzalez, MD, JD, MPH, Claire L. Griffin, MD, London Guidry, MD, Nalaka Gunawansa, MBBS, MS, MCh, Gary Gwertzman, MD, Daniel K. Han, MD, Caitlin W. Hicks, MD MS, Carlos A. Hinojosa, MD, MSc, York Hsiang, MB, ChB, MHSc, Nicole Ilonzo, MD, Lalithapriya Jayakumar, MD, Jin Hyun Joh, MD, PhD, Adam P. Johnson, MD, MPH, Loay S. Kabbani, MD, MHSA, Melissa R. Keller, MD, PhD, Manar Khashram, MBChB, PhD, Issam Koleilat, MD, Bernard Krueger, MD, Akshay Kumar, MD, Cheong Jun Lee, MD, Alice Lee, DO, Mark M. Levy, MD, C. Taylor Lewis, MD, Benjamin Lind, MD, Gabriel Lopez-Pena, MD, Jahan Mohebal, MD, MPH, Robert G. Molnar, MD, MS, Nicholas J. Morrissey, MD, Raghu L. Motaganahalli, MD, Nicolas J. Mouawad, MD, MPH, MBA, Daniel H. Newton, MD, Jun Jie Ng, MD, Leigh Ann O'Banion, MD, John Phair, MD, Zoran Rancic, MD, MSc, PhD, Ajit Rao, MD, Hunter M. Ray, MD, Aksim G. Rivera, MD, Limael Rodriguez, MD, Clifford M. Sales, MD, MBA, Garrett Salzman, MD, Mark Sarfati, MD, Ajay Savlania, MCh, Andres Schanzer, MD, Mel J. Sharafuddin, MD, MS, Malachi Sheahan, MD, Sammy Siada, DO, Jeffrey J. Siracuse, MD, MBA, Brigitte K. Smith, MD, Matthew Smith, MD, PhD, Ina Soh, MD, MS, Rebecca Sorber, MD, Varuna Sundaram, MD, Scott Sundick, MD, MS, Tadaki M. Tomita, MD, Bradley Trinidad, MD, Shirling Tsai, MD, Ageliki G. Vouyouka, MD, Gregory G. Westin, MD, MAS, Michael S. Williams, Jr., MD, Sherry M. Wren, MD, Jane K. Yang, MD, Jeniann Yi, MD, MS, Wei Zhou, MD, Saqib Zia, MD, Karen Woo, MD, MS

PII: S0741-5214(20)31588-3

DOI: <https://doi.org/10.1016/j.jvs.2020.06.112>

Reference: YMVA 11443

To appear in: *Journal of Vascular Surgery*

Received Date: 21 May 2020

Accepted Date: 22 June 2020

Please cite this article as: Chun TT, Judelson DR, Rigberg D, Lawrence PF, Cuff R, Shalhub S, Wohlauser M, Abularrage CJ, Anastasios P, Arya S, Aulivola B, Baldwin M, Baril D, Bechara CF, Beckerman WE, Behrendt C-A, Benedetto F, Bennett LF, Charlton-Ouw KM, Chawla A, Chia MC, Cho S, Choong AMTL, Chou EL, Christiana A, Coscas R, De Caridi G, Ellozy S, Etkin Y, Faries P, Fung AT, Gonzalez A, Griffin CL, Guidry L, Gunawansa N, Gwertzman G, Han DK, Hicks CW, Hinojosa CA, Hsiang Y, Ilonzo N, Jayakumar L, Joh JH, Johnson AP, Kabbani LS, Keller MR, Khashram M, Koleilat I, Krueger B, Kumar A, Lee CJ, Lee A, Levy MM, Lewis CT, Lind B, Lopez-Pena G, Mohebbali J, Molnar RG, Morrissey NJ, Motaganahalli RL, Mouawad NJ, Newton DH, Ng JJ, O'Banion LA, Phair J, Rancic Z, Rao A, Ray HM, Rivera AG, Rodriguez L, Sales CM, Salzman G, Sarfati M, Savlania A, Schanzer A, Sharafuddin MJ, Sheahan M, Siada S, Siracuse JJ, Smith BK, Smith M, Soh I, Sorber R, Sundaram V, Sundick S, Tomita TM, Trinidad B, Tsai S, Vouyouka AG, Westin GG, Williams Jr. MS, Wren SM, Yang JK, Yi J, Zhou W, Zia S, Woo K, Managing Central Venous Access during a Healthcare Crisis, *Journal of Vascular Surgery* (2020), doi: <https://doi.org/10.1016/j.jvs.2020.06.112>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Copyright © 2020 Published by Elsevier Inc. on behalf of the Society for Vascular Surgery.

1 Managing Central Venous Access during a Healthcare Crisis

2

3 Tristen T. Chun, MD, MS¹ Dejah R. Judelson, MD², David Rigberg, MD,¹ Peter F Lawrence,
4 MD,¹ Robert Cuff, MD,³ Sherene Shalhub, MD, MPH,⁴ Max Wohlauer, MD,⁵ Christopher J.
5 Abularrage, MD,⁶ Papapetrou Anastasios, MD, PhD, MSc,⁷ Shipra Arya, MD, SM,⁸ Bernadette
6 Aulivola, MD, MS,⁹ Melissa Baldwin, MD,¹⁰ Donald Baril, MD,¹ Carlos F. Bechara, MD,⁹
7 William E. Beckerman, MD,¹¹ Christian-Alexander Behrendt, MD,¹² Filippo Benedetto, MD,¹³
8 Lisa F. Bennett, MD, MS,¹⁴ Kristofer M. Charlton-Ouw, MD,¹⁵ Amit Chawla, MD,¹⁶ Matthew
9 C. Chia, MD,¹⁷ Sungsin Cho, MD, PhD,¹⁸ Andrew M.T.L. Choong, MBBS, PhD,¹⁹ Elizabeth L.
10 Chou, MD,²⁰ Anastasiadou Christiana, MD,⁷ Raphael Coscas, MD, PhD,²¹ Giovanni De Caridi
11 MD, PhD,¹³ Sharif Ellozy, MD,²² Yana Etkin, MD,²³ Peter Faries, MD,¹⁰ Adrian T. Fung, MD,²⁴
12 Andrew Gonzalez, MD, JD, MPH,²⁵ Claire L. Griffin, MD,²⁶ London Guidry, MD,¹⁶ Nalaka
13 Gunawansa, MBBS, MS, MCh,²⁷ Gary Gwertzman, MD,¹⁰ Daniel K. Han, MD,¹⁰ Caitlin W.
14 Hicks, MD MS,⁶ Carlos A. Hinojosa MD, MSc,²⁸ York Hsiang, MB, ChB, MHSc,²⁴ Nicole
15 Ilonzo, MD,¹⁰ Lalithapriya Jayakumar, MD,²⁹ Jin Hyun Joh, MD, PhD,¹⁸ Adam P. Johnson, MD,
16 MPH,³⁰ Loay S. Kabbani, MD, MHSA,³¹ Melissa R. Keller, MD, PhD,³² Manar Khashram,
17 MBChB, PhD,³³ Issam Koleilat, MD,³⁴ Bernard Krueger, MD,³⁵ Akshay Kumar, MD,³⁶ Cheong
18 Jun Lee, MD,³⁷ Alice Lee, DO,³¹ Mark M. Levy, MD,³⁸ C. Taylor Lewis, MD,²² Benjamin Lind,
19 MD,³⁷ Gabriel Lopez-Pena, MD,²⁸ Jahan Mohebali, MD, MPH,²⁰ Robert G. Molnar, MD, MS,³²
20 Nicholas J. Morrissey, MD,³⁰ Raghu L. Motaganahalli, MD,²⁵ Nicolas J. Mouawad, MD, MPH,
21 MBA,^{32, 39} Daniel H. Newton, MD,³⁸ Jun Jie Ng, MD,¹⁹ Leigh Ann O'Banion, MD,⁴⁰ John Phair,
22 MD,¹⁰ Zoran Rancic, MD, MSc, PhD,³⁵ Ajit Rao, MD,¹⁰ Hunter M. Ray, MD,¹⁵ Aksim G.
23 Rivera, MD,³⁴ Limael Rodriguez, MD,⁵ Clifford M. Sales, MD, MBA,⁴¹ Garrett Salzman, MD,¹

1 Mark Sarfati, MD,²⁶ Ajay Savlania, MCh,⁴² Andres Schanzer, MD,² Mel J. Sharafuddin, MD,
2 MS,⁴³ Malachi Sheahan, MD,¹⁶ Sammy Siada, DO,⁵ Jeffrey J. Siracuse, MD, MBA,⁴⁴ Brigitte K.
3 Smith, MD,²⁶ Matthew Smith, MD, PhD,²² Ina Soh, MD, MS,⁴⁵ Rebecca Sorber, MD,⁶ Varuna
4 Sundaram, MD,²² Scott Sundick, MD, MS,⁴¹ Tadaki M. Tomita, MD,¹⁷ Bradley Trinidad, MD,⁴⁶
5 Shirling Tsai, MD,⁴⁷ Ageliki G. Vouyouka, MD,¹⁰ Gregory G. Westin, MD, MAS,²⁵ Michael S.
6 Williams Jr., MD,⁴⁸ Sherry M. Wren, MD,⁸ Jane K. Yang, MD,¹ Jeniann Yi, MD, MS,⁵ Wei
7 Zhou, MD,⁴⁶ Saqib Zia, MD,⁴⁹ Karen Woo MD, MS,¹

8

9

- 10 1. Department of Surgery, Division of Vascular Surgery, David Geffen School of Medicine
11 at UCLA, Los Angeles, CA
- 12 2. Department of Surgery, Division of Vascular and Endovascular Surgery, University of
13 Massachusetts Medical School, Worcester, MA
- 14 3. Department of Surgery, Division of Vascular Surgery, Spectrum Health/ Michigan State
15 University, Grand Rapids, MI
- 16 4. Department of Surgery, Division of Vascular Surgery, University of Washington, Seattle,
17 WA
- 18 5. Department of Surgery, Division of Vascular Surgery, University of Colorado School of
19 Medicine, Aurora, CO
- 20 6. Department of Surgery, Division of Vascular Surgery and Endovascular Therapy, Johns
21 Hopkins Medical Institutions, Baltimore, MD
- 22 7. Department of Vascular Surgery, General Hospital of Athens KAT, Athens, Greece
- 23 8. Department of Surgery Stanford University School of Medicine, Palo Alto, CA, CA

- 1 9. Department of Surgery, Division of Vascular Surgery and Endovascular Therapy, Loyola
2 University Medical Center, Maywood, IL
- 3 10. Department of Surgery, Division of Vascular Surgery, Icahn School of Medicine at
4 Mount Sinai, New York, NY
- 5 11. Department of Surgery, Division of Vascular Surgery and Endovascular Therapy,
6 Rutgers Robert Wood Johnson, New Brunswick, NJ
- 7 12. Department of Vascular Medicine, Research Group GermanVasc, University Medical
8 Center Hamburg-Eppendorf, Hamburg, Germany
- 9 13. Division of Vascular Surgery, University of Messina, Messina, Italy
- 10 14. Rose Medical Center, HealthOne, Denver, CO
- 11 15. Department of Cardiothoracic and Vascular Surgery, McGovern Medical School at
12 University of Texas Health Science Center at Houston, Houston, TX
- 13 16. Department of Surgery, Division of Vascular Surgery, Louisiana State University Health
14 Sciences Center, New Orleans, LA
- 15 17. Department of Surgery, Division of Vascular Surgery, Northwestern University, Chicago,
16 IL
- 17 18. Department of Surgery, Division of Vascular Surgery, Kyung Hee University School of
18 Medicine, Seoul, South Korea
- 19 19. Division of Vascular and Endovascular Surgery, National University Heart Centre,
20 Singapore, Singapore
- 21 20. Department of Surgery, Division of Vascular Surgery, Massachusetts General Hospital,
22 Boston, MA

- 1 21. Vascular Surgery Department, Ambroise Paré University Hospital, AP-HP, Boulogne-
2 Billancourt, Paris, France
- 3 22. Department of Surgery, Division of Vascular and Endovascular Surgery, Weill Cornell
4 Medicine, New York, NY
- 5 23. Department of Surgery, Division of Vascular and Endovascular Surgery, Zucker School
6 of Medicine at Hofstra/Northwell, Hempstead, NY
- 7 24. Department of Surgery, Division of Vascular Surgery, University of British Columbia,
8 Vancouver, CA
- 9 25. Department of Surgery, Division of Vascular Surgery, Indiana University School of
10 Medicine, Indianapolis, IN
- 11 26. Department of Surgery, Vascular Division, University of Utah, Salt Lake City, UT
- 12 27. Department of Vascular and Transplant Surgery, National Institute of Nephrology,
13 Dialysis and Transplantation, Colombo, Sri Lanka
- 14 28. Department of Surgery, Division of Vascular and Endovascular Surgery, Universidad
15 Nacional Autónoma de México, Instituto Nacional de Ciencias Médicas y Nutrición
16 Salvador Zubirán, CDMX, MX
- 17 29. Department of Surgery, Vascular and Endovascular Division, University of Texas Health
18 Science Center at San Antonio, San Antonio, TX
- 19 30. Department of Vascular Surgery, Columbia University Vagelos College of Physicians
20 and Surgeons, New York, NY
- 21 31. Department of Surgery, Vascular Division, Wayne State University, Detroit, MI
- 22 32. Department of Surgery, Michigan State University, East Lansing, MI
- 23 33. Department of Surgery, University of Auckland, Auckland, New Zealand

- 1 34. Department of Cardiothoracic and Vascular Surgery, Montefiore Medical Center/Albert
2 Einstein College of Medicine, Bronx, NY
- 3 35. Institute of Anesthesiology, Intensive Care Unit for Cardiovascular Surgery, University
4 Hospital Zurich, Faculty of Medicine, University of Zurich, Zurich, Switzerland
- 5 36. Department of Cardiovascular and Thoracic Surgery, Medanta Hospital, Gurgaon, India
- 6 37. Department of Surgery, Division of Vascular Surgery, NorthShore University Health
7 System, Evanston, IL
- 8 38. Department of Surgery, Vascular Division, Virginia Commonwealth University,
9 Richmond, VA
- 10 39. Vascular and Endovascular Surgery, McLaren Health System, Bay City, MI
- 11 40. Department of Surgery, Vascular Division, University of California San Francisco at
12 Fresno, Fresno, CA
- 13 41. The Cardiovascular Care Group, New Jersey
- 14 42. Postgraduate Institute of Medical Education and Research, Chandigarh, India
- 15 43. Department of Vascular Surgery, University of Iowa Healthcare, Iowa City, IA
- 16 44. Department of Surgery, Boston University School of Medicine, Boston, MA
- 17 45. Division of Vascular and Endovascular Surgery, Mayo Clinic, Phoenix, AZ
- 18 46. Department of Surgery, Vascular Division, University of Arizona, Tucson, AZ
- 19 47. Department of Surgery, Vascular Division, VA North Texas Health Care Systems, Dallas
20 TX
- 21 48. Department of Surgery, Vascular and Endovascular Division, St. Louis University School
22 of Medicine, St. Louis, MO

1 49. Department of Surgery, Vascular Division, Rutgers New Jersey Medical School, Newark,
2 NJ

3

4

5

6 Corresponding author:

7 Karen Woo, MD

8 University of California, Los Angeles

9 Department of Surgery

10 Division of Vascular Surgery

11 200 UCLA Medical Plaza Ste 526

12 Los Angeles, CA 90095

13 Office (310) 206-6294

14 Email kwoo@mednet.ucla.edu

15 **ARTICLE HIGHLIGHTS**

16

17 **Type of Research:** Multi-center cross sectional cohort

18 study of experiences with central venous access line

19 teams during the COVID-19 pandemic.

20

21 **Key Findings:** Participants from 60 hospitals in 13

22 countries contributed data. 75% of line teams included a

23 vascular surgery attending physician. 2,657 central

1 venous lines were placed at 20 of the participating sites
2 with 11 (0.41%) iatrogenic access complications
3 associated with procedures performed by the line team.

4

5 **Take home Message:** Implementation of a dedicated
6 central venous access line team during health care
7 emergencies, with staffing by physicians with central
8 venous access expertise, a dedicated line cart, specific
9 anatomic sites for different venous access needs, and a
10 method to track complications, can improve outcomes
11 and reduce iatrogenic complications.

12

13

14

15

16 **Table of Contents Summary**

17

18 Implementation of dedicated central venous access line teams during health care emergencies,
19 with staffing by physicians with central venous access expertise, a dedicated line cart,
20 recommended sites for access, and a method to track complications, can improve access delivery
21 and may reduce the risk of iatrogenic complications and mortality.

1 **Abstract**

2 *Introduction:* During the COVID-19 pandemic, central venous access line teams were
3 implemented at many hospitals throughout the world to provide access for critically ill patients.
4 The objective of this study was to describe the structure, practice patterns and outcomes of these
5 vascular access teams during the COVID-19 pandemic.

6 *Methods:* We conducted a cross sectional, self-reported study of central venous access line teams
7 in hospitals afflicted with the COVID-19 pandemic. In order to participate in the study, hospitals
8 were required to meet one of the following criteria: a) development of a formal plan for a central
9 venous access line team during the pandemic, b) implementation of a central venous access line
10 team during the pandemic, c) placement of central venous access by a designated practice group
11 during the pandemic as part of routine clinical practice, or d) management of an iatrogenic
12 complication related to central venous access in a patient with COVID-19.

13 *Results:* Participants from 60 hospitals in 13 countries contributed data to the study. Central
14 venous line teams were most commonly composed of vascular surgery and general surgery
15 attending physicians and trainees. Twenty sites had 2,657 lines placed by their central venous
16 access line team or designated practice group. During that time, there were 11 (0.4%) iatrogenic
17 complications associated with central venous access procedures performed by the line team or
18 group at those 20 sites. Triple lumen catheters, Cordis® catheters and non-tunneled hemodialysis
19 catheters were the most common types of central venous lines placed by the teams. Eight (14%)
20 sites reported experience placing central venous lines in prone, ventilated patients with COVID-
21 19. A dedicated line cart was used by 35 (59%) of hospitals. Less than 50% (24, 41%) of the
22 participating sites reported managing thrombosed central lines in COVID-patients. Twenty-three

1 of the sites managed 48 iatrogenic complications in patients with COVID-19 (including
2 complications caused by providers outside of the line team or designated practice group).

3 *Conclusions:* Implementation of a dedicated central venous access line team during a pandemic
4 or other healthcare crisis is a way by which physicians trained in central venous access can
5 contribute their expertise to a stressed healthcare system. A line team composed of physicians
6 with vascular skill sets provides relief to resource-constrained ICU, ward, and emergency
7 medicine teams with a low rate of iatrogenic complications relative to historical reports. We
8 recommend that a plan for central venous access line team implementation be in place for future
9 healthcare crises.

10

11

12

1 **Introduction:**

2 The novel coronavirus, SARS-CoV-2, has caused 7,293,307 cases of Coronavirus
3 Disease 2019 (COVID-19) worldwide (as of June 10, 2020) and 413,126 deaths. Of those cases,
4 1,990,112 have been in the United States with 112,441 associated deaths between February 6,
5 2020 and June 10, 2020¹. Approximately 5-10% of patients with COVID-19 require admission to
6 the intensive care unit and mechanical ventilation²⁻³. In these critically ill patients, the rates of
7 septic shock and acute kidney injury are 20% and 15%, respectively⁴⁻⁵. As a result, these patients
8 often require central venous access for the infusion of vasoactive agents and/or hemodialysis.

9 In the COVID-19 crisis, overburdened health care systems throughout the world have had
10 to address the need to provide central venous access for the unprecedented dramatic influx of
11 critically ill patients, particularly during the surge period of the pandemic. As a result, the
12 procedure of placing central venous access, which is normally a routine occurrence in critical
13 care units, has created unique challenges during the COVID-19 pandemic given the limited
14 providers available to manage the extraordinary increase in critically ill patients. The limited
15 resources may lead to central venous access procedures being performed by less experienced
16 and/or overworked physicians, which results in an increased rate of serious complications⁶.
17 Furthermore, central venous access procedures can result in physicians being occupied for a
18 prolonged period by a single patient while the issues of other acutely ill patients are not being
19 addressed. In the case of a COVID-19 positive patient, the central venous access procedure
20 includes not only the time required to perform the procedure, but also the additional time
21 required to don and doff the added personal protective equipment required.

1 During the COVID-19 pandemic, central venous access line teams have been developed
2 at many hospitals throughout the world to handle the access needs of all patients in the hospital,
3 freeing physicians with less experience in central venous access and those who are overburdened
4 by acute and critical demands to focus on management of other patients requiring their attention<sup>7-
5 ⁸. The teams often consist of vascular surgeons, general surgeons, interventional radiologists,
6 anesthesiologists, intensivists, and interventional cardiologists who have been trained and have
7 extensive experience in central venous access, as well as experience identifying and managing
8 the complications associated with central venous access procedures⁹⁻¹⁰. For example, to meet the
9 increased demand for critical care providers at the University of Massachusetts, vascular
10 surgeons formed a “Surgical Workforce Access Team (SWAT)” in order to best leverage the
11 skillsets of vascular surgery division members and provide the best service to the hospital and to
12 their colleagues⁷. At Mount Sinai Hospital in New York, physicians recognized a dramatic
13 increase in the rate of central line complications and the resulting urgent vascular interventions.
14 In response, the vascular surgeons created a line team⁸.</sup>

15 While central line teams and protocols for line placement and management have been
16 described in the past, those efforts have been focused on reducing central line-associated
17 bloodstream infections rather than addressing a pressing need during a healthcare disaster¹¹⁻¹³.
18 Within the context of early isolated single-institution reports, we sought to provide a multi-
19 institutional experience of line teams during the pandemic. The objective of this study was to
20 describe the structure, practice patterns, and outcomes of these line teams on central venous
21 access procedures and their related complications.

22 **Methods:**

1 We conducted a cross-sectional, self-reported study of structured central venous access
2 line teams and the physician groups providing central venous access in hospitals afflicted by the
3 COVID-19 pandemic. In order to participate in the study, hospitals were required to meet one of
4 the following criteria: a) development of a formal plan for a central venous access line team
5 during the pandemic, b) implementation of a central venous access line team during the
6 pandemic, c) placement of central venous access by a designated practice group during the
7 pandemic as part of routine clinical practice, or d) management of an iatrogenic complication
8 related to central venous access in a patient with COVID-19

9 This study was a collaborative effort between the Vascular Low Frequency Disease
10 Consortium (VLFDC) and the Vascular Surgery COVID-19 Collaborative (VASCC). The
11 VLFDC is a multi-institutional collaboration, initiated 20 years ago, and designed to investigate
12 uncommon vascular diseases¹⁴. The VASCC was established on March 2, 2020 to study the
13 impact of the ongoing COVID-19 pandemic on vascular surgical care¹⁵, using an international
14 registry.

15 The Institutional Review Board of the University of California Los Angeles (UCLA)
16 deemed this study protocol exempt as a quality improvement project.

17 *Database development*

18 The primary investigators (KW, TC, DJ, DR) initially developed the registry data
19 elements by determining factors important to the structure and function of central venous access
20 line teams' experience of line placement during the pandemic, as well as iatrogenic
21 complications associated with line placement. The draft registry was reviewed by a group of
22 physician investigators with central venous line placement expertise and revised in an iterative

1 fashion until no further modifications were recommended by the group. This established the final
2 standardized dataset for collection that constitutes the basis of this study.

3 *Data collection*

4 The study was disseminated through the VLFDC and VASCC electronic mailing lists and
5 social media. Study data were collected and managed using REDCap (Research Electronic Data
6 Capture), a web-based data collection mechanism designed for research¹⁶. Data entry into the
7 registry opened on April 22, 2020 and closed on May 4, 2020. Study participants were required
8 to record responses to all items in the database. Participants were contacted via electronic mail
9 by the UCLA vascular research center for clarification of any discrepancies in the submitted data
10 and missing data.

11 Participants were required to enter their hospital characteristics, utilization of central
12 venous access line teams during the pandemic, types of patients and locations in which the line
13 team services were offered, team composition, team availability, criteria for activation and
14 termination of their services, and anatomic sites used for access. Each institution was asked to
15 provide details regarding any iatrogenic complications associated with central venous line
16 placement, and if available, the total number of central venous access procedures performed
17 during the time that the line team or designated practice group placing central lines was in place.
18 Each institution was also given the opportunity to provide insight regarding successful
19 management of central venous access during the pandemic.

20 **Results**

21 *Demographics*

1 Participants from 60 hospitals in 13 countries contributed data to the study
2 (Appendix A). Fifty-eight of the hospitals had plans in place for a central venous access line
3 team, had implemented the line team, or had a designated practice group placing central venous
4 lines for the hospital outside of a formal line team structure. Two of the participating hospitals
5 had not developed or implemented a line team or designated a group to place lines, but had
6 managed an iatrogenic complication related to central venous access in a patient with COVID-
7 19. Most of the hospitals that participated were urban, academic, university-affiliated hospitals
8 with more than 400 beds (Table 1). Thirty-one of the hospitals had developed and implemented a
9 central venous access line team specifically for the pandemic, while five hospitals had a plan for
10 a line team but had not yet implemented it. Twenty-five of the participating hospitals had a
11 physician group placing central venous lines as part of their routine clinical practice, without
12 being designated as a “line team.” Eight of the hospitals that implemented a line team had a
13 central venous access line team in existence prior to the pandemic, with four making no changes
14 once the pandemic started. Two changed the PPE protocols for their line teams with the onset of
15 the pandemic. One made services available on the weekends and ensured that attending
16 physicians were physically present in the hospital at all times. One had a pre-existing medical
17 proceduralist team which remained in place with the addition of a surgical team to supplement or
18 take over their responsibilities when the medical specialists get called to take care of patients.

19 Central venous access line teams were most commonly composed of vascular and
20 general surgery attending physicians and trainees, with some hospitals including attending
21 physicians and trainees of other specialties such as interventional radiology and anesthesiology
22 (Figure 1). Nearly all of the line teams were developed served or intended to serve patients who
23 had tested positive for the SARS-CoV-2 virus (COVID-19+) in the intensive care unit setting

1 (ICU) (42, 96%) as well as patients under investigation for SARS-CoV-2 infection (COVID-
2 19PUI) in the ICU (40, 90%). Fewer line teams included patients who had tested negative for the
3 SARS-CoV-2 virus (COVID-19-) in the ICU (28, 66%). Most line teams also provided service
4 for COVID-19+ and COVID-19PUI patients on the floor setting (28, 64%). Some line teams
5 provided services for COVID-19+ (25, 57%) and COVID-19PUI (22, 50%) patients in the
6 emergency department.

7 The plan to utilize the services of a central venous access line team during the pandemic
8 was most commonly initiated by the vascular surgery division/department (15, 34%) or critical
9 care team (11, 25%). The burden of COVID-19+ patients exceeding a critical threshold at the
10 institution, where providers with training were present but overwhelmed, was cited as one of the
11 reasons for implementing the line team by 22 (50%) of hospitals. The importance of minimizing
12 line placement complications was cited as one of the reasons for implementation by 23 (52%) of
13 hospitals. The majority of line teams made their services available daily at all hours (28, 64%),
14 while at some hospitals (5, 12%), the timing of line team service availability varied by the phase
15 of the pandemic and the stress on the resources in their hospital. These hospitals required
16 exceeding a critical volume threshold for the central venous access line team to become
17 activated. The criteria for terminating the line team services included a combination of: 1)
18 reduction of hospitalized COVID patients to below a critical threshold (64%), 2) increased
19 availability of other providers with line placement skills (25%), and 3) line team members
20 returning to regular duties (41%).

21 *Central venous access line team characteristics*

1 In the 58 hospitals placing lines, six sites (10%), had no trainees involved in
2 central venous line placement procedures. At eleven hospitals (19%), the attending physician
3 was in the room during every line placement procedure. Of the 41 remaining hospitals, 30 had
4 trainees that were at least at post-graduate year three level performing the central venous access
5 procedures, with attending physicians immediately available.

6 Triple lumen catheters (TLCs), Cordis® catheters, non-tunneled hemodialysis catheters
7 (NTHDCs) and tunneled hemodialysis catheters (THDCs) were the most common types of
8 central venous lines placed (Figure 2). Six of the hospitals also performed peripherally inserted
9 central catheters (PICC); however, they reported that this practice was in place prior to the
10 pandemic and remained unchanged.

11 Among the 44 hospitals with line teams in place or planned, additional line team services
12 provided, beyond central venous line placement during the COVID-19 pandemic, included:
13 arterial line placement (82.8%), orogastric/nasogastric tube placement (18%), tube thoracostomy
14 (16%), Foley catheter placement (10%), intubation (7%), tracheostomy (5%), gastric tube
15 placement (2%), and rectal tube placement (2%). For the 31 hospitals with line teams in place,
16 the reported numbers of central venous line placements performed over the seven days preceding
17 participation in this study varied from <10 to >40, with the most common category being >40
18 (Table 1).

19 *Anatomic considerations*

20 The internal jugular veins were the preferred sites for TLC and hemodialysis catheter
21 (HDC) placement prior to the COVID-19 pandemic (Table 2); these continued to be the
22 preferred sites during the pandemic for COVID-19+, COVID-19PUI and COVID-19- patients.

1 However, during the pandemic, the participating sites used the internal jugular and subclavian
2 veins less frequently than prior to the pandemic, while the great saphenous (GSV) and popliteal
3 veins (PV) were used more frequently. For supine COVID-19+ patients, the first choice for TLC
4 placement was the right internal jugular vein in 31 (52.5%) hospitals and the left internal jugular
5 vein in 22 (37.3%). The first-choice location for HDC placement was the right internal jugular
6 vein in 46 (82.1%) of the hospitals. Similar patterns were found for COVID-19PUI (Table 2).

7 Most participating sites considered similar anatomic locations for COVID-19+ and
8 COVID-19- patients; however, 18 (30.5%) sites reported that their preferences for venous access
9 in COVID-19+ patients were different from COVID-19- patients, with the most common reason
10 being the ease of accessibility and the likelihood of kinking the catheters if the patient required
11 prone positioning. Other considerations included the risk of pneumothorax and the proximity to
12 the patient's airway, potentially increasing the risk of infection to the providers performing the
13 procedure. In addition, 16 (27%) sites considered renal failure or impending renal failure
14 requiring dialysis as a factor in choosing anatomic location for TLCs or HDCs. Most reported
15 preserving the right internal jugular vein for HDCs and avoiding the femoral veins for HDCs for
16 potential prone positioning required for COVID-19 treatment.

17 Eight (14%) sites reported experience with placing central venous lines in prone,
18 ventilated COVID-19+ patients, with no associated complications. Six of the sites always
19 delayed line placement until the patient returned to the supine position, or they requested that the
20 patient be returned to the supine position for the procedure. One site placed the lines with the
21 patient remaining in the prone position. Two sites placed the line with the patient remaining in
22 the prone position if they could safely access the vein laterally. In this population of patients who
23 required prone positioning, TLCs continued to be placed in either the right or the left internal

1 jugular veins, the femoral vein, or the great saphenous vein. HDCs were placed exclusively in
2 the right internal jugular vein. Three lines were placed while the patient remained in the prone
3 position: 1) a TLC placed in the popliteal vein, 2) a NTHDC placed in the right internal jugular
4 vein, and 3) a TLC placed in the right internal jugular vein. Standard line placement techniques
5 were used with ultrasound guidance and percutaneous Seldinger technique.

6 All 58 sites placing central venous lines during the COVID-19 pandemic used
7 ultrasound guidance during line placement and nearly all participants (52, 90%) reported
8 obtaining a chest X-ray (CXR) to confirm line placement for internal jugular or subclavian lines
9 in COVID-19+ patients. Those who did not obtain a CXR acknowledged that this deviated from
10 their normal practice. Their rationale for not utilizing a CXR was to limit exposure of hospital
11 staff and radiology technologists, while conserving personal protective equipment (PPE).

12 *Supplies and PPE utilization*

13 A dedicated line cart was used at 35 (59%) hospitals. The most common items
14 stored in these line carts were: kits for TLCs, HDCs, Cordis® catheters (100%), sterile gloves
15 (97%), sterile gowns (97%), sterile preparation sticks (94%), sterile gauze (94%), ultrasound
16 probe covers (94%), selection of syringes (91%), sterile saline flushes (91%), sutures (91%),
17 masks (91%), and bouffant hats (85%) (Appendix B).

18 PPE utilization patterns by line teams in COVID-19+ patients and COVID-19PUI
19 were similar (Table 3). A small but significant number of line teams continued to use N95 masks
20 with or without surgical masks, even in COVID-19- patients (Table 3). When asked if hospitals
21 experienced an increased incidence of needle sticks to providers associated with central line

1 placement during the COVID-19 pandemic, 28 (47%) responded “no” and 31 (52%) “did not
2 know”.

3 *Prevention and management of thrombosed central lines*

4 Less than 50% (24, 41%) of the participating sites in this study reported
5 managing thrombosed central lines in COVID-19+ patients: 19 (33%) sites reported managing at
6 least one thrombosed TLC, 21 (36%) HDC, and 2 (3%) Cordis® catheters. Over half of the sites
7 (32, 54%) believed that central lines were more likely to thrombose in COVID-19+ patients,
8 compared to COVID-19- patients, due to hypercoagulability. Most also believed that HDCs were
9 more likely to thrombose in COVID-19+ patients than any other type of central venous lines.

10 Only 13 (22%) participating sites recommended varying types of routine
11 anticoagulation in COVID-19+ patients to maintain central line patency, including: prophylactic
12 dosing of unfractionated heparin (4 sites), therapeutic dosing of unfractionated heparin (1 site),
13 prophylactic dosing of low molecular weight heparin (5 sites), and therapeutic dosing of low
14 molecular heparin (2 sites). The two remaining hospitals anticoagulated all COVID-19+
15 patients, regardless of whether the patient had a central venous access line in place. The majority
16 of the participants who recommended anticoagulation were concerned about a high rate of
17 thrombosis in COVID-19+ patients and recommended anticoagulation to minimize resource
18 utilization.

19 Only 7 (12%) participating sites were routinely changing central lines. Of those 7 sites, 5
20 reported that routine changing of lines was part of their regular practice, regardless of the
21 pandemic. One site changed the line every three days, one every four days, four every seven days
22 and one every eight days.

1 *Complications and deaths*

2 Twenty participating sites reported 2,657 lines *placed by their designated group or line team*
3 *in COVID-19+, COVIDPUI and/or COVID-19- patients*; there were 11 (0.4%) iatrogenic
4 complications associated with central venous access line placement procedures performed by the
5 designated group or line team at those sites. These consisted of two inadvertent placements of a
6 catheter into an artery, seven instances of hematoma or active bleeding at catheter sites, one
7 instance of pneumothorax and one air embolism. The air embolism was in a COVID-19+ patient
8 who was not intubated and the patient expired shortly thereafter. This was the only death directly
9 related to an iatrogenic venous access complication.

10 A total of 48 iatrogenic complications of central venous line placement *in the COVID-*
11 *19+ population* were managed by 23 (38%) participating sites, including complications
12 associated with procedures performed by providers *outside of their line team or designated*
13 *group* (Table 4). The most common type of complication was inadvertent placement of a catheter
14 into an artery. In 20 of the complications, the participating site believed something could have
15 been done differently during the initial access attempt to prevent the complication. In almost all
16 of these cases, the participating site believed that a combination of a more experienced operator,
17 meticulous use of ultrasound, and maintaining wire control at all times could have prevented the
18 complication.

19 With respect to the COVID-19+ population, in one case of inadvertent puncture of the
20 artery, the wire was left in the femoral artery and the patient was anticoagulated, since the patient
21 was deemed too unstable for intervention. In three of the cases of inadvertent placement of a
22 catheter into an artery, the patient was deemed too unstable from COVID-19 to undergo an

1 intervention. In all but three of the complications in the COVID-19+ population, the participating
2 sites indicated that they would have managed the iatrogenic complication in a COVID-19-
3 patient in a similar manner to what was done in the COVID-19+ patient. For three
4 complications, the sites stated they may have considered more aggressive surgical or
5 interventional management if the patient had not been COVID-19+.

6 **Discussion:**

7 We describe the formation, implementation and results of dedicated central venous access
8 line teams led by physicians with central venous access expertise during the COVID-19
9 pandemic. These dedicated line teams served as an invaluable resource in stressed health care
10 systems. This is aptly demonstrated by the 2,657 lines placed by 20 of the line teams. Each of
11 these lines represents an instance where the line team enabled the ICU team to focus on the care
12 of an unprecedented high volume of critically ill patients, rather than spend time preparing for
13 the procedure, donning and doffing PPE and performing the procedure. These line teams
14 represent “bringing together elements to ensure an effective response”, which is a key point that
15 is repeatedly emphasized in disaster management¹⁷.

16 The rapid spread of the pandemic exposed a lack of disaster preparedness in hospitals
17 worldwide¹⁸. Most healthcare disasters occur without notice¹⁹. In order to optimize outcomes
18 during a disaster, plans for managing a disaster need to be in place prior^{17,19}. The lessons learned
19 from this initial line service experience can be readily applied to future healthcare crises and
20 future surges of the COVID-19 pandemic. In fact, at the time of this writing (June 10, 2020),
21 stay-at-home orders are being lifted across the US. Since the stay-at-home order was lifted in

1 Arizona on May 16, cases have increased by 108% in that state with an associated increase in
2 hospitalizations and strain on the healthcare system²⁰.

3 Vascular surgeons are uniquely trained to lead dedicated central venous access line
4 teams, since a vascular practice usually encompasses routine percutaneous arterial and venous
5 access, invariably using ultrasound guidance. The technical skills necessary to perform a high
6 volume of these procedures, with a low complication rate, are critical for these teams to be of
7 value. Based on the experiences of the participants in this study, we have identified a set of best
8 practices for central venous line placement during times when hospital systems are stressed by
9 disasters such as the COVID-19 pandemic.

10 Standard Practices

11 *Line Team Implementation:* Each institution should determine an appropriate schedule for
12 line team activation, based on available resources and individual institutional needs. Ideally, the
13 team should be available throughout the day, and any limitations should be communicated to the
14 intensive care units and emergency rooms. The ramp-up and ramp-down of the line team should
15 be individualized to the needs of the institution and the central venous access service line. A
16 number of participants in this study highlighted the importance of understanding variations in
17 individual institutional resource allocation, with this being a key to providing service at the
18 optimal time and place.

19 *Line Cart:* An adequately stocked line cart increases the efficiency of line placement
20 procedures. This cart should have all the supplies and PPE necessary to safely perform central
21 venous line placements and remain outside the room to reduce cross contamination. Having an
22 appropriately stocked cart, as pointed out by a number of participants, reduces donning and

1 doffing of PPE, minimizes potential provider exposure, and allows for a more streamlined and
2 efficient placement of venous access. Appendix C demonstrates equipment we recommend on a
3 line cart, including PPE.

4 *PPE:* It is paramount that proceduralists be provided with appropriate PPE. We found
5 that the majority of our respondents were following best practices for PPE utilization – wearing
6 an N95 mask, covered by a surgical mask, protective eye wear, bouffant/surgical cap, and a
7 gown and gloves for COVID-19+ patients. A number of sites recommended that there should be
8 no more than two providers in the room, with a “runner” outside the room, who can retrieve
9 additional supplies as needed, in order to preserve PPE and minimize exposure.

10 *Location of Central Lines:* The preferred location of central venous access lines was
11 relatively consistent across respondents. Given the high incidence of acute renal failure and need
12 for acute hemodialysis in the COVID-19+ population, most centers preferably placed central
13 lines in the left internal jugular vein, reserving the right internal jugular vein for non-tunneled
14 hemodialysis lines. Given the high rate of COVID-19+ ICU patients requiring prone positioning,
15 femoral lines were avoided; several centers reported placing popliteal vein lines in these patients.
16 Subclavian lines were also discouraged, given the known increased incidence of pneumothorax
17 over internal jugular lines. Several centers used 55cm hemodialysis lines intended for tunneled
18 placement, in a non-tunneled fashion when femoral dialysis access was needed. The cuff
19 remained outside the patient, with the intent that the extra catheter length and stiffer catheter
20 material would help to reduce kinking and displacement when the patient required prone
21 positioning.

1 *Ultrasound guidance:* All centers utilized ultrasound guidance when performing central
2 venous access. Notably, participating sites believed that over half of the iatrogenic complications
3 they managed could have been prevented with meticulous use of ultrasound guidance.
4 Ultrasound guidance has become the standard of care in placement of central lines and should
5 continue to be used in disaster situations such as the COVID-19 pandemic, despite the additional
6 time required to thoroughly clean the machine between uses²¹. Participants recommended
7 confirming wire position in the long axis ultrasound view and using a sterile cover over the entire
8 ultrasound probe and machine during the procedure to reduce the risk of cross-contamination.
9 Wireless ultrasound transducers may be particularly useful in this clinical scenario⁽¹⁰⁾.

10 *Post Placement Confirmation:* In critically ill patients, reducing complications is
11 paramount, and early identification of complications is a key to patient survival. Thus, obtaining
12 a post-procedure chest X-ray to confirm the tip location and that no pneumothorax has occurred
13 continues to be an important step used by the majority of hospitals, even in a limited resource
14 situation. Careful examination of the images by the treating physician, to rule out pneumothorax,
15 is of particular importance in intubated patients, especially with higher pressure ventilator
16 settings.

17 *Needlestick Prevention:* We were reassured to see that there was a low incidence of
18 needlestick injuries. In stressful situations, it is important to continue to practice safely,
19 particularly with sharps and sharps disposal. Stressful and unfamiliar working conditions, lack of
20 adequate protective medical/technical equipment and poor work routines are known to contribute
21 to needlestick injuries²². Using an experienced, well-prepared team allows for the repetition and
22 expertise needed to reduce needle stick injuries. During this particular pandemic, patients that are
23 COVID-19+ or COVID-19PUI must both be handled with the same care, caution, and PPE.

1 *Management of Hypercoagulability and Line Thrombosis:* Hypercoagulability in the
2 COVID-19+ population is well established²³⁻²⁵. We found variability among hospitals in
3 reporting their experience with thrombosed central lines; consequently, prevention strategies also
4 differed. The majority of thrombosed lines were NTHDC, and the thrombosis presumably
5 occurred during continuous veno-venous hemofiltration, a known complication of a low flow
6 hemodialysis session²⁶. However, we were surprised to find the large number of TLCs that also
7 thrombosed. Some participants recommended running continuous infusions of low-dose
8 heparinized saline through any lines that are not being used for other infusions.

9 *Complications:* Complications secondary to central venous line placement are always
10 expected; however, the overall complication rate of 0.4% when central venous lines are placed
11 by dedicated line teams is significantly lower than the rate of up to 15% that has been previously
12 published²⁷⁻²⁸. The incidence of arterial cannulation during central venous access has been
13 reported to be in the range of 4.2%-9.3% of all line placements²⁹. In a study of 539 central
14 venous catheter placements under ultrasound and fluoroscopy guidance, 486 of the lines were
15 primarily placed by a surgical trainee³⁰. The associated complication rate was 8.4%, 93% of
16 which were arterial punctures. This suggests a dedicated line team may not only increase
17 efficiency of provider utilization in a pandemic but may also reduce complications in a fragile at-
18 risk population.

19 *Limitations*

20 As with all studies using retrospective, self-reported data, there is a possibility of
21 reporting error or inaccuracy. To minimize this risk we standardized the data points with specific
22 definitions and carefully reviewed the submitted data to identify any discrepancies. All

1 discrepancies were clarified individually with the participating investigator. Our study would be
2 strengthened by a matched contemporaneous comparison group of hospitals that did not
3 implement a central venous access line team or designate a group to place lines. Another
4 valuable comparison would be the rate of complications at participating hospitals before the
5 pandemic. However, these types of studies require a complex study design with recruitment of
6 matched hospitals and abstraction of data that was not readily available during the pandemic.
7 This was not feasible at the time of the study, but could be performed in the future to quantify the
8 impact of line teams on the incidence of iatrogenic central venous access complications. Lacking
9 this, we relied on historical data in the literature for iatrogenic complication rates of central
10 venous line procedures and anatomical preferences for central venous line placement.

11 This data was collected at the height of the pandemic for many participating institutions.
12 As such, we sought to describe practice patterns that could possibly be useful to other institutions
13 in preparing for future waves of the pandemic or other health care crises, using data that was
14 easily accessible to participating institutions during the potentially chaotic time. This study
15 serves as a hypothesis-generating study that brings up several granular issues relevant to the
16 effectiveness of line teams, requiring more laborious data extraction that should be investigated
17 in the future. A study examining the cost effectiveness of maintaining a line cart and dedicating
18 personnel to line teams, balanced against the potential decrease in procedural complications and
19 increased efficiency, would provide insight into the financial burden of implementing this
20 intervention. Comparing the degree of change in volume of central line placements before the
21 pandemic to during the pandemic, when the line teams were in place, would quantify the
22 magnitude of the line placement challenge.

1 The unit of analysis in this study was the hospital. Patient-specific data were collected
2 only in the case of complications and line placement in prone patients. Future studies utilizing
3 patient-specific data addressing issues such as whether the rates of line sepsis were influenced by
4 the pandemic would provide further insight into the impact of the pandemic on management of
5 central venous access.

6 As physicians learn more about managing patients with COVID-19, practice patterns may
7 change with regard to line team structure and function, preferred anatomic locations and other
8 technical issues. A follow-up study in the future regarding “lessons learned” from central venous
9 access during the pandemic and the associated changes in practice patterns in response would be
10 valuable.

11 **Conclusion:**

12 The implementation of a dedicated central venous access line team is a way in which
13 physicians trained in percutaneous central venous access can make a contribution to a stressed
14 healthcare system during a pandemic or other healthcare crisis. A line team composed of
15 physicians with vascular skill sets provides relief to resource-constrained ICU, ward, and
16 emergency medicine teams with a low rate of iatrogenic complications relative to historical
17 reports. We recommend that a plan for central venous access line team implementation be in
18 place for future healthcare emergencies; including staffing, a dedicated line cart,
19 recommendations on the optimal anatomic site and technique, as well as a method to track
20 complications.

21

1 **Acknowledgements:**

2 We are deeply grateful Gabriela Flores for her unfailing dedication as project coordinator.

3 We thank Morad Sallam, M.D. for assistance in testing and refining the data collection

4 instrument.

5 The project described was supported by the National Center for Advancing Translational

6 Sciences (NCATS), National Institutes of Health (NIH), through grant UL1TR001881 and the

7 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of

8 Health (NIH) (NIDDK1K08DK107934).

9

References:

1. COVID-19 Dashboard by the Center for Systems Science and Engineering at Johns Hopkins University. Available at:
<https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6>, Accessed 10th June 2020.
2. Pericàs JM, Hernandez-Meneses M, Sheahan TP, Quintana E, Ambrosioni J, Sandoval E, et al. COVID-19: from epidemiology to treatment. *Eur Heart J.* 2020;41(22):2092–2112.
3. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention [published online ahead of print, 2020 Feb 24]. *JAMA.* 2020;10.1001/jama.2020.2648.
4. Ng JJ, Luo Y, Phua K, Choong AMTL. Acute kidney injury in hospitalized patients with coronavirus disease 2019 (COVID-19): A meta-analysis [published online ahead of print, 2020 May 8]. *J Infect.* 2020;S0163-4453(20)30280-2.
5. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study [published correction appears in *Lancet.* 2020 Mar 28;395(10229):1038] [published correction appears in *Lancet.* 2020 Mar 28;395(10229):1038]. *Lancet.* 2020;395(10229):1054–1062.
6. Vannucci A, Jeffcoat A, Ifune C, Salinas C, Duncan JR, Wall M. Special article: retained guidewires after intraoperative placement of central venous catheters. *Anesth Analg.* 2013;117(1):102–108.

- 1 7. Sheth PD, Simons JP, Robichaud DI, Ciaranello AL, Schanzer A. Development of a
2 surgical workforce access team in the battle against COVID-19 [published online ahead
3 of print, 2020 Apr 30]. *J Vasc Surg.* 2020;S0741-5214(20)31099-5.
- 4 8. Ilonzo N, Vouyouka A, Han D, Tadros R, Kim SY, Love B, et al. The Importance of a
5 Centralized Line Service during the COVID-19 Pandemic [published online ahead of
6 print, 2020 May 14]. *J Vasc Surg.* 2020;S0741-5214(20)31158-7.
- 7 9. American Society of Anesthesiologists Task Force on Central Venous Access, Rupp SM,
8 Apfelbaum JL, Blitt C, Caplan RA, Connis RT, Domino KB, et al. Practice guidelines for
9 central venous access: a report by the American Society of Anesthesiologists Task Force
10 on Central Venous Access. *Anesthesiology.* 2012;116(3):539-573.
- 11 10. Scoppettuolo G, Biasucci DG, Pittiruti M. Vascular access in COVID-19 patients: Smart
12 decisions for maximal safety [published online ahead of print, 2020 May 5]. *J Vasc*
13 *Access.* 2020;1129729820923935.
- 14 11. Conwell P, Aniskiewicz M, Ghidini J, DeVaux L, Perazella M, Giullian J. A Hospital-
15 Based Program to Reduce Central Line-Associated Bloodstream Infections among
16 Hospitalized Patients Receiving Hemodialysis Using a Central Venous Catheter for
17 Vascular Access. *Nephrol Nurs J.* 2019;46(6):587-590.
- 18 12. Legemaat MM, Jongerden IP, van Rens RM, Zielman M, van den Hoogen A. Effect of a
19 vascular access team on central line-associated bloodstream infections in infants admitted
20 to a neonatal intensive care unit: a systematic review. *Int J Nurs Stud.* 2015;52(5):1003-
21 1010.

- 1 13. Pathak R, Gangina S, Jairam F, Hinton K. A vascular access and midlines program can
2 decrease hospital-acquired central line-associated bloodstream infections and cost to a
3 community-based hospital. *Ther Clin Risk Manag.* 2018;14:1453-1456.
- 4 14. Lawrence PF, Baril DT, Woo K. Investigating uncommon vascular diseases using the
5 Vascular Low Frequency Disease Consortium [published online ahead of print, 2020 Jan
6 18]. *J Vasc Surg.* 2020;S0741-5214(19)32781-8.
- 7 15. Mouawad NJ, Cuff RF, Hultgren R, Chuen J, Galeazzi E, Wohlauer M. The Vascular
8 Surgery COVID-19 Collaborative (VASCC) [published online ahead of print, 2020 Apr
9 22]. *J Vasc Surg.* 2020;S0741-5214(20)31054-5.
- 10 16. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic
11 data capture (REDCap)--a metadata-driven methodology and workflow process for
12 providing translational research informatics support. *J Biomed Inform.* 2009;42(2):377-
13 381.
- 14 17. Aitken P, Leggat P. Considerations in mass casualty and disaster management. In:
15 Blaiivas M, editor. *Emergency medicine: an international perspective.* Rijeka:
16 IntechOpen; 2012. p. 145-182.
- 17 18. Sasangohar F, Jones SL, Masud FN, Vahidy FS, Kash BA. Provider Burnout and Fatigue
18 During the COVID-19 Pandemic: Lessons Learned from a High-Volume Intensive Care
19 Unit [published online ahead of print, 2020 Apr 9]. *Anesth Analg.*
20 2020;10.1213/ANE.0000000000004866.
- 21 19. Rasmussen TE, Koelling EE. A military perspective on the vascular surgeon's response to
22 the COVID-19 pandemic. *J Vasc Surg.* 2020;71(6):1821-1822.

- 1 20. Christie B, Weber P, DeMillo A, Chandler K, Reeves J, Anderson B, et al. Alarming rise
2 in virus cases as states roll back lockdowns. Associated Press News. 10th June, 2020.
3 Available at: <https://apnews.com/feb4c26d9364497cf82ee7c0c1b1b3d5>, accessed 11th
4 June, 2020.
- 5 21. Lamperti M, Bodenham AR, Pittiruti M, Blaiwas M, Augoustides JG, Elbarbary M, et al.
6 International evidence-based recommendations on ultrasound-guided vascular
7 access. *Intensive Care Med.* 2012;38(7):1105–1117.
- 8 22. Wicker S, Stirn AV, Rabenau HF, von Gierke L, Wutzler S, Stephan C. Needlestick
9 injuries: causes, preventability and psychological impact. *Infection.* 2014;42(3):549–
10 552.
- 11 23. Spiezia L, Boscolo A, Poletto F, Cerruti L, Tiberio I, Campello E, et al. COVID-19-
12 Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute
13 Respiratory Failure. *Thromb Haemost.* 2020;120(6):998–1000.
- 14 24. Wichmann D, Sperhake JP, Lütgehetmann M, Steurer S, Edler C, Heinemann A, et al.
15 Autopsy Findings and Venous Thromboembolism in Patients With COVID-19 [published
16 online ahead of print, 2020 May 6]. *Ann Intern Med.* 2020;M20-2003.
- 17 25. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM,
18 et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-
19 19. *Thromb Res.* 2020;191:145–147.
- 20 26. Oudemans-van Straaten HM, Wester JPJ, de Pont ACJM, Schetz MRC. Anticoagulation
21 strategies in continuous renal replacement therapy: can the choice be evidence
22 based?. *Intensive Care Med.* 2006;32(2):188–202.

- 1 27. McGee DC, Gould MK. Preventing complications of central venous catheterization. N
2 Engl J Med. 2003;348(12):1123-1133.
- 3 28. Merrer J, De Jonghe B, Golliot F, Lefrant JU, Raffy B, Barre E, et al. Complications of
4 femoral and subclavian venous catheterization in critically ill patients: a randomized
5 controlled trial. JAMA. 2001;286(6):700-707.
- 6 29. Kornbau C, Lee KC, Hughes GD, Firstenberg MS. Central line complications. Int J Crit
7 Illn Inj Sci. 2015;5(3):170-178.
- 8 30. Hameeteman M, Bode AS, Peppelenbosch AG, van der Sande FM, Tordoir JH.
9 Ultrasound-guided central venous catheter placement by surgical trainees: a safe
10 procedure?. J Vasc Access. 2010;11(4):288-292.

Table 1. Hospital characteristics and central venous line placement volume

	Hospitals with line team in place or planned n=44 (%)	Groups placing lines at their hospital outside of line team n=14 (%)
Hospital characteristics		
Urban	44 (100)	14 (100)
Academic university affiliated	34 (77)	11 (79)
Non-university affiliated	4 (9)	2 (14)
teaching	3 (7)	1 (7)
Community/private	4 (9)	2 (14)
Public	1 (7)	5 (11)
Veterans affairs		
Hospital size by baseline beds		
100-199	5 (11)	1 (7)
200-299	3 (7)	1 (7)
300-399	6 (14)	1 (7)
>400	30 (68)	11 (79)
	Hospitals with line teams in place n=31 (%)	
Line placements in previous 7 days*		
0-10	7 (23)	NA
10-20	9 (29)	
20-30	2 (7)	
30-40	2 (7)	
>40	11 (36)	

*Line placements in the 7 days preceding data entry into the study

Table 2. Anatomic preferences for central venous catheter placements by COVID-19 status

	R IJ n (%)	L IJ n (%)	R SC n (%)	L SC n (%)	Fem n (%)	GSV n (%)	Pop n (%)
<i>All anatomic locations considered viable</i>							
Prior to Pandemic	59 (97)	58 (95)	41 (67)	39 (64)	52 (85)	2 (3)	0 (0)
COVID-19+	52 (85)	50 (82)	27 (44)	26 (43)	48 (79)	4 (7)	2 (3)
COVID-19PUI	55 (90)	51 (84)	27 (44)	27 (44)	49 (80)	4 (7)	1 (2)
COVID-19-	59 (97)	58 (95)	34 (56)	32 (53)	49 (80)	2 (3)	0 (0)
<i>1st choice for supine patient</i>							
COVID-19+							
TLC	31 (53)	22 (37)	2 (3)	0 (0)	4 (7)	0 (0)	0 (0)
HDC	46 (82)	0 (0)	2 (3)	0 (0)	8 (14)	0 (0)	0 (0)
COVID-19PUI							
TLC	30 (51)	23 (39)	2 (3)	0 (0)	4 (7)	0 (0)	0 (0)
HDC	45 (80)	0 (0)	2 (3)	0 (0)	9 (16)	0 (0)	0 (0)

R IJ: right internal jugular vein; L IJ: left internal jugular vein; R SC: right subclavian vein; L SC: left subclavian vein; Fem: femoral vein; GSV: greater saphenous vein; Pop: popliteal vein; COVID-19+: patient who has tested positive for SARS-CoV-2 virus; COVID-19PUI: patient under investigation for SARS-CoV-2 infection; COVID-19-: patient who has not tested positive for SARS-CoV-2 virus; TLC: triple lumen catheter; HDC: hemodialysis catheter

Table 3. Personal protective equipment used during placement of central venous lines populations by COVID-19 status

	COVID-19+ (%)	COVID-19PUI (%)	COVID-19- (%)
Surgical mask without N95	1 (2)	2 (3)	41 (67)
N95 without surgical mask	15 (25)	13 (21)	6 (10)
N95 with surgical mask over	45 (74)	46 (75)	12 (20)
Powered air-purifying respirator	10 (16)	8 (13)	2 (3)
Face shield	54 (89)	55 (90)	36 (59)
Gown	55 (90)	54 (89)	55 (90)
Bunny suit with hood	5 (8)	4 (7)	0 (0)
Bunny suit without hood	3 (5)	3 (5)	0 (0)
Bouffant/surgical cap	52 (85)	52 (85)	48 (79)
Goggles	2 (3)	1 (2)	0 (0)

COVID-19+: patient who has tested positive for SARS-CoV-2 virus; COVID-19PUI: patient under investigation for SARS-CoV-2 infection; COVID-19-: patient who has not tested positive for SARS-CoV-2 virus

Table 4. Iatrogenic complications of central venous line placement in COVID-19+ patients managed by participating sites.

Complication	Total Number of cases	Cases related to line team procedure	Anatomic Location				Initial Management Strategy	Initial Management Success
			IJ / Carotid	SC	Fem	Other		
Inadvertent arterial puncture with wire in place prior to catheter placement	3	0	2	0	1		Pull line and hold pressure (1) Open surgical repair (1) Other (1)	Yes Yes *
Inadvertent arterial puncture with dilator in place prior to catheter placement	2	0	1	0	0	Descending aorta	Pull line and hold pressure (1), Endovascular mgmt w stent (1)	Yes Yes
Inadvertent arterial placement with catheter still remaining in artery	16	1	5	6	4	Brachio-cephalic artery	Pull line and hold pressure (5), Endovascular mgmt w balloon (2), Closure device (1), Endovascular mgmt w stent graft (1), Open surgical repair (3), Used as arterial line then pulled (1) Other (3)*	Yes Yes Yes Yes Yes *
Inadvertent arterial puncture with no catheter remaining in artery but active extravasation present	2	0	0	1	1		Pull line and hold pressure (2)	Yes
Catheter or wire fracture/embolization	3	0	0	0	1	aorta right atrium	Open surgical retrieval (1) Anticoagulation (2)	Yes
Hematoma or active bleeding at catheter site with catheter in place and catheter in	10	6	8	1	1		Pull line and hold pressure (10)	Yes

correct position								
Pneumothorax	11	1	4	5	0	2 unknown	Tube thoracostomy (11)	Yes
Air embolism	1	1	1	0	0		None attempted	No

*see text; IJ: internal jugular, SC: subclavian, fem: femoral

Journal Pre-proof

Journal Pre-proof

Figure 1.





Figure 2. Types of central venous lines placed by line teams (n=44).

TLC: triple lumen catheter; NTHDC: non-tunneled hemodialysis catheter; THDC: tunneled hemodialysis catheter; VV ECMO: veno-venous extracorporeal membrane oxygenation; AV ECMO: arterio-venous extracorporeal membrane oxygenation; PD: peritoneal dialysis; PICC: peripherally inserted central catheter; Others include: Infusaports, Hickman catheters and small bore sheaths for potential ECMO candidates

Figure 1. Central Venous Access Line Team Composition. VS: Vascular Surgery; GS: General Surgery; IR: Interventional Radiology; Card: Cardiology; CTS: Cardiothoracic Surgery; Med: Medicine; Anes: Anesthesia.

*Percentage of Line Teams that Include Attending Physicians and Trainees of Each Specialty

Figure 2. Types of central venous lines placed by line teams (n=44). TLC: triple lumen catheter; NTHDC: non-tunneled hemodialysis catheter; THDC: tunneled hemodialysis catheter; VV ECMO: veno-venous extracorporeal membrane oxygenation; AV ECMO: arterio-venous extracorporeal membrane oxygenation; PD: peritoneal dialysis; PICC: peripherally inserted central catheter; Others include: Infusaports, Hickman catheters and small bore sheaths for potential ECMO candidates

Table 1. Hospital characteristics and central venous line placement volume. *Line placements in the 7 days preceding data entry into the study

Table 2. Anatomic preferences for central venous catheter placements by COVID-19 status. R IJ: right internal jugular vein; L IJ: left internal jugular vein; R SC: right subclavian vein; L SC: left subclavian vein; Fem: femoral vein; GSV: greater saphenous vein; Pop: popliteal vein; COVID-19+: patient who has tested positive for SARS-CoV-2 virus; COVID-19PUI: patient under investigation for SARS-CoV-2 infection; COVID-19-: patient who has not tested positive for SARS-CoV-2 virus; TLC: triple lumen catheter; HDC: hemodialysis catheter

Table 3. Personal protective equipment used during placement of central venous lines populations by COVID-19 status. COVID-19+: patient who has tested positive for SARS-CoV-2 virus; COVID-19PUI: patient under investigation for SARS-CoV-2 infection; COVID-19-: patient who has not tested positive for SARS-CoV-2 virus

Table 4. Iatrogenic complications of central venous line placement in COVID-19+ patients managed by participating sites. *see text; IJ: internal jugular, SC: subclavian, fem: femoral

Appendix A. Hospitals represented in this study.

Appendix B: Items placed on dedicated line carts used by line teams.

Appendix C: Recommended items on a dedicated line cart

Appendix A. Hospitals represented in this study.

Country	State	Hospital
Canada		Vancouver General Hospital
France		Ambroise Paré University Hospital, AP-HP
Germany		University Medical Center Hamburg-Eppendorf
Greece		General Hospital of Athens KAT
India		Medanta Hospital
		Postgraduate Institute of Medical Education and Research
Italy		Policlinico Gaetano Martino
Korea (South)		Kyung Hee University Hospital at Gangdong
Mexico		Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
New Zealand		Waikato Hospital
Singapore		National University Hospital
Sri Lanka		National Institute of Nephrology Dialysis and Transplantation
Switzerland		University Hospital Zurich
	AZ	Banner University Medical Center-Tucson
	AZ	Mayo Clinic Hospital
	CA	Community Regional Medical Center
	CA	Olive View- UCLA Medical Center
	CA	Palo Alto Veterans Affairs Medical Center
	CA	Ronald Reagan UCLA Medical Center
	CA	Veterans Affairs Greater Los Angeles
	CO	Rocky Mountain Regional Veterans Affairs Medical Center
	CO	Rose Medical Center
	CO	University of Colorado Anschutz Medical Campus
	IA	University of Iowa Hospitals and Clinics
	IL	Loyola University Medical Center
	IL	NorthShore University Health System
	IL	Northwestern Memorial Hospital
	IN	Eskenazi Health
	IN	Indiana University Health Methodist Hospital
	IN	Indiana University Health North Hospital
	IN	Indiana University Health West Hospital
	LA	Our Lady of the Lake
	LA	West Jefferson Medical Center
	MA	Boston Medical Center
	MA	Massachusetts General Hospital
	MA	University of Massachusetts Medical Center
	MD	The Johns Hopkins Hospital
	MI	Henry Ford Hospital
	MI	McLaren Bay Region
	MI	McLaren Flint

	MO	St. Louis University Hospital
	NJ	Overlook Medical Center
	NJ	Rutgers Robert Wood Johnson University Hospital
	NJ	University Hospital
	NY	Jacobi Medical Center
	NY	Montefiore Medical Center
	NY	Mount Sinai Brooklyn
	NY	The Mount Sinai Hospital
	NY	Mount Sinai Queens
	NY	New York-Presbyterian Columbia University Medical Center
	NY	New York- Presbyterian Queens
	NY	North Shore University Hospital, Northwell Health
	NY	Weill Cornell Medicine
	TX	Audie L Murphy Veterans Affairs Hospital
	TX	Dallas Veterans Affairs Medical Center
	TX	Memorial Hermann-Texas Medical Center
	TX	University of Texas Health Science Center at San Antonio University Hospital
	UT	University of Utah Hospital
	VA	Virginia Commonwealth University Medical Center
	WA	University of Washington Medical Center

Appendix B: Items placed on dedicated line carts used by line teams.

Item	(%)
Central line kits	100
Sterile gloves	97.1
Sterile gowns	97.1
Sterile preparation sticks	94.3
Sterile gauze	94.3
Ultrasound probe cover	94.3
Selection of syringes	91.4
Sterile saline flush	91.4
Sutures	91.4
Masks	91.4
Bouffant hats	85.7
Selection of hypodermic needles	80.0
Surgical towels	80.0
Tape	77.1
Selection of sterile drapes	77.1
Face shields	77.1
Lidocaine	74.3
Micropuncture sets	74.3
3-way stopcock	71.4
Antimicrobial dressing	71.4

Appendix C: Recommended items on a dedicated line cart

PPE:

Gloves
Gowns
Bouffant head covering
Masks: surgical, N95
Face Shields
Boot covers

Non-sterile items:

Tape
Coban
Arm boards

Sterile items:

Central Line Kits
Non-tunneled hemodialysis access kits
Arterial line kits (Arrow, micropuncture)
12" extension tubing
Surgical towels
Drapes: for arterial lines, central lines
Sterile gloves
Sterile gowns
Sterile preparation sticks
Sterile gauze
Selection of syringes
Selection of hypodermic needles
Suture
Ultrasound probe cover
Lidocaine
3-way stopcock
Antimicrobial dressing